Vertex Pharmaceuticals Director Departs; Financials Filed
Ticker: VRTX · Form: 8-K · Filed: Feb 10, 2025 · CIK: 875320
Sentiment: neutral
Topics: director-departure, financial-results
Related Tickers: VRTX
TL;DR
Vertex director out, financials filed. Keep an eye on next steps.
AI Summary
Vertex Pharmaceuticals Incorporated announced on February 4, 2025, the departure of Dr. Paul J. W. Stone, a member of its Board of Directors. The company also reported on its results of operations and financial condition, and filed related financial statements and exhibits. The filing does not specify the reason for Dr. Stone's departure or provide detailed financial figures in the provided text.
Why It Matters
The departure of a board member can signal internal changes or strategic shifts within a company, while the filing of financial results provides investors with an update on the company's performance.
Risk Assessment
Risk Level: low — The filing primarily reports on a director's departure and standard financial updates, with no immediate indication of significant financial distress or major negative events.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- Dr. Paul J. W. Stone (person) — Departing Director
- February 4, 2025 (date) — Date of earliest event reported
- Massachusetts (location) — State of incorporation
- Boston (location) — Principal executive offices city
FAQ
What was the effective date of Dr. Paul J. W. Stone's departure from the Board of Directors?
The filing indicates February 4, 2025, as the date of the earliest event reported, which includes the departure.
Does the filing provide the reason for Dr. Stone's departure?
The provided text of the filing does not specify the reason for Dr. Stone's departure.
What are the main items reported in this 8-K filing?
The filing covers Results of Operations and Financial Condition, Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers, Compensatory Arrangements of Certain Officers, and Financial Statements and Exhibits.
What is Vertex Pharmaceuticals' state of incorporation and fiscal year end?
Vertex Pharmaceuticals is incorporated in Massachusetts and its fiscal year ends on December 31.
What is the principal executive office address for Vertex Pharmaceuticals?
The principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts 02210.
Filing Stats: 1,347 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2025-02-10 16:08:20
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
- $1,000,000 — Mr. Wagner to receive a base salary of $1,000,000 and a target annual bonus of 100% of ba
- $127,000 — tiveposition who received approximately $127,000 in total compensation in 2024 and also
Filing Documents
- vrtx-20250204.htm (8-K) — 32KB
- ex-991_q42024.htm (EX-99.1) — 243KB
- 0000875320-25-000029.txt ( ) — 426KB
- vrtx-20250204.xsd (EX-101.SCH) — 2KB
- vrtx-20250204_lab.xml (EX-101.LAB) — 21KB
- vrtx-20250204_pre.xml (EX-101.PRE) — 12KB
- vrtx-20250204_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 10, 2025, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 10, 2025, Vertex Pharmaceuticals Incorporated (the "Company") announced the retirement of Stuart A. Arbuckle, the Company's Executive Vice President and Chief Operating Officer, effective on July 1, 2025. The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company and the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company. Mr. Wagner will remain the Company's Executive Vice President and Chief Financial Officer following his appointment. The appointment of Messrs. Wagner and McKechnie will be effective on July 1, 2025. Mr. Wagner has held the position of Executive Vice President and Chief Financial Officer since April 2019. For additional biographical information on Mr. Wagner, please see the Company's Form 10-K filed with the Securities and Exchange Commission on February 15, 2024. In connection with his appointment, the Company entered into a new employment agreement and a new change of control agreement with Mr. Wagner, w
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated February 10, 2025 . 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: February 10, 2025 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer